With the goal of discovering new starting points for the development of Hsp90 CTD inhibitors for cancer treatment, a library of diverse commercially available compounds was docked to the Hsp90β CTD binding site in the conformation from the MD simulation trajectory, from which we had previously derived our structure-based pharmacophore model. The gene discussed is HSP90AB1; the disease is cancer.